X4 Pharmaceuticals (XFOR) Net Margin (2018 - 2025)
X4 Pharmaceuticals (XFOR) posted Net Margin of 931.31% for Q4 2025, up 44.83% on a QoQ basis from 1688.1% in Q3 2025, and up 184617.0% year-over-year from N/an in Q4 2024.
X4 Pharmaceuticals (XFOR) Net Margin (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals' Net Margin history runs 4 years deep, the most recent figure standing at 931.31% for Q4 2025.
- Quarterly Net Margin rose 184617.0% year-over-year to 931.31% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 225.52% (up 123928.0% YoY) and the FY2025 annual result came in at 225.52%, up 124104.0% from the prior year.
- Net Margin was 931.31% for Q4 2025 at X4 Pharmaceuticals, up from 1688.1% in the prior quarter.
- Across five years, Net Margin topped out at 16132.68% in Q2 2024 and bottomed at 6544.82% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | -931.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -931.31% |
| Sep 30, 2025 | -1,688.10% |
| Jun 30, 2025 | -1,305.17% |
| Mar 31, 2025 | 0.96% |
| Dec 31, 2024 | -2,777.48% |
| Sep 30, 2024 | -6,544.82% |
| Jun 30, 2024 | 16,132.68% |
| Mar 31, 2020 | -371.27% |
| Dec 31, 2018 | -343.94% |